Journal
FRONTIERS IN PHARMACOLOGY
Volume 6, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2015.00090
Keywords
antiretroviral; drug resistance; HIV; integrase inhibitors
Categories
Ask authors/readers for more resources
Dolutegravir (DIG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DIG shows a limited cross-resistance profile. More interestingly, clinical resistance mutations to DIG in treatment-naive patents have not been observed to this date. This review summarizes recent studies on resistance mutations to DIG and on our understanding of the mechanisms of resistance to DIG as well as future directions for research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available